Systemic chemotherapy for metastatic melanoma

Seminars in Oncology

Volumn 15, Issue 6, 1988, Pages 569-577

  Mc Clay, Edward F ^a   Mastrangelo, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DETORUBICIN; LOMUSTINE; MITOLACTOL; TAMOXIFEN; TAXOL; VINDESINE;

CARDIOTOXICITY; HUMAN; LEUKOPENIA; MELANOMA; METASTASIS; NAUSEA; NEUROPATHY; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; HUMAN; INTERFERONS; MELANOMA; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0024272177     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Cutaneous melanoma
2. Phase II trial of Bisantrene in patients with metastatic melanoma
3. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma
4. Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma
5. Phase II trial of esorubicin in patients with advanced melanoma
6. Phase II study of IV menogaril in patients with malignant melanoma: A National Cancer Institute of Canada trials group study
7. Phase II evaluation of spirogermanium in malignant melanoma A South-west Oncology Group Study
8. Prednimustine in advanced malignant melanoma: A Phase II study
9. Ifosfamide: Review
10. Amsacrine (AMSA)—A clinical review
11. Phase II trial of 4-Demethoxydaunorubicin in patients with advanced malignant melanoma
12. Phase II study of mitomycin in disseminated malignant melanoma
13. Phase II studies of homoharringtonine in patients with advanced malignant melanoma, sarcoma, and head and neck, breast and colorectal carcinomas
14. Phase II trial of Carboplatin versus Iproplatin in disseminated malignant melanoma
15. Phase II trial of carboplatin in advanced malignant melanoma
16. A Phase I study of Iproplatin (CHIP) in advanced malignant melanoma
17. Treatment of metastatic malignant melanoma with Tiazofurin: A Phase II study
18. The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colorectal, head and neck, renal carcinomas and malignant melanoma
19. Preparation it activate antitumorale experimental din nouvel antibiotique semi-synthetique: La diethoxyacetoxy-4 daunouebicine (33921 R.P.)
20. Pharmacokinetic, toxicologic and chemotherapeutic properties of detrorubicin in mice: A comparative study with daunorubicin and adriamycin
21. Detrorubicin—An active anthracycline in untreated metastatic melanoma
22. Phase I trial of Taxol given as a 24 hour infusion every 21 days: Responses observed in metastatic melanoma
23. Phase II Pilot study of Taxol in patients with malignant melanoma
24. Phase I–II eldisene (vindesine sulfate) trials
25. Phase I trial of vindesine in patients with advanced cancer
26. Vindesine in patients with metastatic malignant melanoma: A Southwest Oncology Group Study
27. Positive Phase II trial of dibromodulcitol in patients with metastatic melanoma refractory of DTIC and a nitrosourea
28. Phase II study of mitolactol in metastatic malignant melanoma
29. Phase II study of mitolactol in advanced malignant melanoma
30. Cisplatin, vinblastine and bleomycin in the treatment of metastatic melanoma: A Phase II study of the Southeastern Cancer Study Group
31. Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea and cyclophosphamide in previously untreated patients with malignant melanoma
32. Combination chemotherapy with dacarbazine and lomustine in disseminated malignant melanoma
33. Single dose dacarbazine and dactinomycin in advanced malignant melanoma
34. Treatment of metastatic malignant melanoma with vinblastine, dacarbazine and cisplatin: A report from the Cancer and Leukemia Group B
35. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma
36. Cytarabine and cisplatin in advanced malignant melanoma
37. Phase II study of the combination of carmustine and 6-thioguanine in advanced malignant melanoma
38. Phase II study of the combination of vinblastine plus cisplatin administered by continuous 120-hour infusion for patients with advance malignant melanoma
39. Treatment of metastatic malignant melanoma with dacarbazine and cisplatin
40. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma
41. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma
42. Cisplatin and nifedipine: Synergistic cytotoxicity against murine solid tumors and their metastases
43. Verapamil enhancement of antitumor effect of cis-diamino dichloroplatinum (II) in nude mouse grown human neuroblastoma
44. Reversal of acquired resistance to doxarubicin in P388 murine leukemia cells by tamoxifen and other treparanol anologues
45. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretary cell line
46. Lomustine, bleomycin and cisplatin in patients with metastatic malignant melanoma
47. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) in advanced malignant melanoma
48. Dacarbazine, vindesine and cisplatin combination chemotherapy in advanced malignant melanoma: A Phase II study
49. Combination cytotoxic chemotherapy with procarbazine, vincristine and lomustine (POC) in disseminated malignant melanoma: 8 years follow up
50. Lomustine, vincristine and procarbazine in the treatment of metastatic melanoma
51. Dose: A critical factor in cancer chemotherapy
52. High dose chemotherapy without autologous bone marrow transplantation in melanoma
53. Phase I/II trials of WR-2721 and cisplatin
54. WR-2721 and high dose cisplatin: An active combination in the treatment of metastatic melanoma
55. Highdose cisplatin (DDP) and WR-2721 (WR) in metastatic melanoma
56. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma
57. A randomized Phase I/II study of continuous versus intermittant intravenous interferon gamma in patients with metastatic melanoma
58. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules
59. Three consecutive Phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma
60. Comparison of intramuscular and intravenous recombinant alfa-2 interferon in melanoma and other cancers
61. Role of recombinant interferon alpha-2 in treatment of advanced malignant melanoma
62. Recombinant interferon alfa-2a in advanced malignant melanoma A Phase I–II study in combination with DTIC